Why Rimonabant Acomplia

Lose Weight One Miracle Drug - Rimonabant Acomplia

Rimonabant acomplia diet weight loss pills are approved now and will be available on sale in all of 25 European Union Countries in July.

The European Commission gave permission for the sale of Rimonabant acomplia prescription weight loss drugs to treat obesity and weight loss with a BMI ( body mass index) of 30 or above as well as for smoking cessation treatments.

"The approval of Rimonabant Acomplia in the European Union is important news for obese and overweight patients with additional cardiometabolic risk factors such as type 2 diabetes or dyslipidaemia who will now have access to an innovative treatment option," said Sanofi CEO Jean-François Dehecq.

Sanofi said that after the launch of Acomplia (Rimonabant) in the United Kingdom, it will be launched during the second half of 2006 in Denmark, Ireland, Germany, Finland and Norway as well.

Sanofi provided no updates on the status of the approval process at the U.S. Food and Drug Administration.

"Now we shall take care with this product, we shall work hard in conjunction with the medical community in order to insure that is will be prescribed to patients who stand to benefit the most from it," Dehecq said.

Sanofi CEO Jean-François Dehecq Dehecq said those likely to gain the most benefit from Rimonabant Acomplia are "obese patients with serious metabolic and cardiometabolic risks."

A 20-mg per day version has been authorized for all 25 EU member states, with the first launch set for the UK in July.

Acomplia, also known as rimonabant Acomplia, is used to treat weight loss and obesity diseases for patients at risk of heart complications or type II diabetes.

Acomplia Rimonabant Video

Buy Rimonabant Acomplia Online